Clinical Trial Finder

Inclusion Criteria:

• - Any gender.

• - Aged 18+ - Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected as part of the baseline survey).

• - Diagnosed with only one of the following conditions: - Long Covid.

• - Documented clinical history of confirmed or suspected acute COVID-19 infection a minimum of 3 months prior to contact with the study team.

• - Formal diagnosis of Long Covid from a physician.

• - Post-treatment Lyme disease syndrome.

• - Diagnosis will be based on participants meeting either Group 1 or Group 2 criteria of the Columbia Clinical Trial Network PTLDS diagnostic criteria: - Group 1.

Well-defined Lyme disease meeting CDC Surveillance Definition Erythema Migrans History of possible exposure to a high incidence county or state (or an adjacent area) Erythema migrans rash.

• - EM 1: EM rash diagnosed by HCP previously (either in person or telemedicine) - EM 1A: MOA self-report & medical record documentation of rash > 5 cm.

• - EM 1B: MOA: self-report and medical record documentation of EM rash but not size.

• - EM 1C: MOA: self-report & rash misdiagnosed in medical record as cellulitis/spider bite.

• - EM 1D: MOA: self-report and either: photo of EM or Class 1 lab test confirmation within 4 weeks of illness onset OR.

• - Disseminated "objective" manifestation with lab test confirmation of Bb infection.

• - Clinical history includes at least one of the following symptoms/signs, which are not better accounted for by another cause (MOA: medical records and/or self-report).

• - Neurologic: Lymphocytic Meningitis ; Encephalitis; Encephalomyelitis Cranial Neuritis (especially facial palsy); Radiculoneuropathy; Other Neurologic Signs (with objective measures) : Encephalopathy, Polyneuropathy.

• - Carditis: 2nd or 3rd degree AV block; Myocarditis; Pericarditis.

• - Lyme arthritis: Recurrent joint swelling in one or more joints.

• - Dermatologic: Disseminated EM ("satellite") or Acrodermatitis atrophicans AND.

• - Lab test Confirmation (requires at least one of the Class 1 lab tests) (MOA: self-report & documentation) - Group 2.

Probable.

• - 2A.

Chronic Multisystem Symptoms attributed to Lyme disease (insufficient to meet Group 1) and not better explained by another diagnosis and patient has evidence of positive lab results on a Class 1 lab test (or 4 of 10 bands for IgG Western blot (WB)) (MOA: self-report with lab documentation Class 1 lab test confirmation (excluding IgM WB) Highly suggestive IgG WB (4 of 10 bands) OR.

• - 2B.

EM rash by history after exposure to a Lyme-endemic area but not previously diagnosed by a HCP and no photo or Class 1 lab test confirmation is available (MOA: self-report) OR.

• - 2C.

Viral like illness (not better explained by other cause) with indeterminate or + enzyme immunoassay (EIA) with positive IgM WB or positive Class 1 lab test (within 4 weeks of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM) (MOA: medical records, lab test and self-report) (MOA: lab test and self-report) OR.

• - 2D.

Viral like illness (not better explained by other cause) with indeterminate or positive EIA with positive IgM WB or positive Class 1 lab test (within 6 months of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM)

• - (MOA: medical records, lab test and self-report) - (MOA: lab test and self-report) - ME/CFS.

• - Formal diagnosis of ME/CFS prior to 2020 from a physician.

• - Actively symptomatic such that the 2011 International Criteria for ME/CFS is met at time of screening.

Exclusion Criteria:

• - Current use of antiplatelet or anticoagulation regimen.

• - Diagnosis of an autoimmune condition such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.

• - Pregnancy or lactation.

• - Known allergy to earthworms (Lumbrokinase is a supplement that is derived from earthworms) - Past medical history of a bleeding or clotting disorder.

- Has a scheduled surgery during, or immediately after, the study period

Arms

Experimental: Long Covid

Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.

Experimental: Post-treatment Lyme Disease Syndrome

Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.

Experimental: ME/CFS

Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.

Interventions

Dietary Supplement: - Lumbrokinase

Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.